qnexa® new prescription diet pill
Qnexa is a possible new prescription diet pill that is showing remarkable weight loss properties in clinical testing. Its fate rests in the FDA's decision on acceptance. Read the rest
vivus announces fda acceptance of qnexa new drug application for
Qnexa (phentermine and topiramate) is a new drug in development for the treatment of obesity. Qnexa information includes news, clinical trial results and side effects. Read the rest
qnexa® obesity drug information and news
Qnexa is a trial medication being tested to treat obesity and showing some positive r! esults. Read the rest
vivus submits qnexa new drug application to the fda for the
Qnexa (phentermine and topiramate) is a new drug in development for the treatment of obesity . Qnexa information includes news, clinical trial results and side effects. Read the rest
obesity vivus welcome
Three pivotal phase 3 trials evaluating Qnexa in over 4,500 patients as a treatment for obesity were recently completed under a Special Protocol Assessment by the U.S Read the rest
phenterminetopiramate wikipedia the f! ree encyclopedia
The combination of the drugs phentermi! ne and topiramate (trade name Qnexa) is an investigational medication for the treatment of obesity and related conditions such Read the rest
fda reconsiders weight loss drug qnexa cbs news
The FDA is again considering approval of an experimental weight loss drug it rejected a year ago over concerns about potential heart problems and birth Read the rest
weight loss drug qnexa abc news abcnews com daily news
The FDA rejected an application from drug maker Vivus to have Qnexa approved for the treatment of obesity, citing possible health risks. But the results of a phase 3 Read the rest
obesity drug qnexa helps patients drop 22 pounds is it safe
(CBS) Big news for big people: in a new drug company-funded study, high doses of the weight loss drug Qnexa helped patients lose an average of 22 pounds Read the rest
could qnexa be the next big diet pill? abc news
Patients taking a novel diet drug that combines the stimulant phentermine with the anticonvulsant topiramate lost an average of 37 pounds over a year with significant Read the rest